Skip to main content
. 2019 Nov 27;2019(11):CD012631. doi: 10.1002/14651858.CD012631.pub2

4.2. Analysis.

4.2

Comparison 4 Sensitivity analysis: serious adverse events ‐ at maximum follow‐up, Outcome 2 Serious adverse events ‐ at maximum follow‐up ‐ cumulated.